The Enterprise Value as of November 2024 (TTM) for AlloVir, Inc. (ALVR) is 6.59M

According to AlloVir, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.59M. This represents a change of -87.44% compared to the average of 52.46M of the last 4 quarters.

AlloVir, Inc. (ALVR) Historical Enterprise Value (quarterly & annually)

How has ALVR Enterprise Value performed in the past?

The mean historical Enterprise Value of AlloVir, Inc. over the last ten years is 735.80M. The current 6.59M Enterprise Value has changed -10.43% with respect to the historical average. Over the past ten years (40 quarters), ALVR's Enterprise Value was at its highest in in the December 2020 quarter at 2.27B. The Enterprise Value was at its lowest in in the June 2024 quarter at -11695257.88.

AlloVir, Inc. (ALVR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of AlloVir, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

AlloVir, Inc. (ALVR) Average Enterprise Value

How has ALVR Enterprise Value performed in the past?

The current Enterprise Value of AlloVir, Inc. (ALVR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

AlloVir, Inc. (ALVR) Enterprise Value vs. Peers

How is ALVR’s Enterprise Value compared to its peers?

AlloVir, Inc.’s Enterprise Value is less than Anebulo Pharmaceuticals, Inc. (45.92M), less than Mineralys Therapeutics, Inc. (603.45M), greater than AN2 Therapeutics, Inc. (5.46M), less than Aerovate Therapeutics, Inc. (48.13M), less than Adagene Inc. (59.89M), greater than Homology Medicines, Inc. (-103303255.00), less than Stoke Therapeutics, Inc. (501.96M), greater than Atreca, Inc. (-8620212.00), less than Black Diamond Therapeutics, Inc. (159.92M), less than 4D Molecular Therapeutics, Inc. (249.45M), less than Acrivon Therapeutics, Inc. Common Stock (201.35M), less than Cullinan Oncology, Inc. (810.70M), less than Agios Pharmaceuticals, Inc. (2.36B), less than Crinetics Pharmaceuticals, Inc. (4.87B), greater than Inhibrx Biosciences, Inc. (411.31K), less than Merus N.V. (3.08B), less than Lyell Immunopharma, Inc. (251.92M), less than Kronos Bio, Inc. (14.20M), less than AnaptysBio, Inc. (909.29M),

Build a custom stock screener for AlloVir, Inc. (ALVR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AlloVir, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

AlloVir, Inc. (ALVR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like AlloVir, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.